Navigation Links
Resverlogix Completes Patient Recruitment for ASSERT Trial
Date:2/8/2010

se and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factor
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
2. Resverlogix Presenting at Biotech Showcase
3. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
4. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
5. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
6. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
7. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
8. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
9. Resverlogix Provides Quarterly Update
10. Resverlogix Board of Directors Update
11. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... England , May 24, 2013 ... Mundipharma angefertigt – Bei der ... , 91 % der Teilnehmer einer groß ... nur 20 % laut GINA [*] -Definition [1] ... dass Menschen mit Asthma generell einer von vier Denkweisen ...
(Date:5/23/2013)... ELMSFORD, N.Y. , May 23, 2013  BioScrip, ... the Company will present at the Jefferies 2013 Global ... the Grand Hyatt New York. ... and Hai Tran , Chief Financial ... 11:30 a.m. Eastern Daylight Time.   About ...
(Date:5/23/2013)... Patheon Inc ., a leading provider ... pharmaceutical industry, will host a complimentary webinar on “Cleaning ... Tuesday, June 4, 2013 at 11 a.m. Eastern Standard ... comply with regulations for cleaning validation. Many companies ... and little evaluation of risk. Some companies have ...
(Date:5/23/2013)... Francisco, CA (PRWEB) May 23, 2013 ... who encourage all types of inventions. They focus on ... now noticing this community gravitate toward bringing their ideas ... the DIY Biology Movement, works on making projects using ... the DNA of plants to make them glow with ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... may inadequately stimulate a patient,s heart while undergoing a ... pulses mixing with the electronic pulses from the pacemaker. ... patient undergoing the MRI scan, according to research published ... Online . MRI is an imaging technique that ...
... the Nanyang Technological University (NTU) signed the Memorandum of ... Research (CNRS) and the Thales Group of Companies to ... are meeting again in Singapore to inaugurate the CNRS-International-NTU-Thales ... at the Research Techno Plaza, the CINTRA Laboratory aims ...
... FREMONT, Calif., Dec. 16 WaferGen Biosystems, Inc. (OTC ... analysis systems, today announced that it will be launching ... gene-expression profiling using its SmartChip(TM) Real-Time PCR System. ... microRNA panel of 885 microRNAs on a single SmartChip. ...
Cached Biology Technology:FDA researchers identify new MRI safety risk for patients with pacemakers 2New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 4
(Date:5/23/2013)... cancer patients unnecessarily undergo surgery or harsh treatments ... slow-growing and aggressive forms of the disease. Researchers ... Medical Institutes are developing technology that allows patients ... relatively mild treatments or take drastic measures. , ... an associate professor of biomedical engineering at Case ...
(Date:5/23/2013)... in treating cerebral palsy with autologous cord blood. Following ... year old boy had been in a persistent vegetative ... months after treatment with the cord blood containing stem ... the child learned to speak simple sentences and to ... study, dispel the long-held doubts about the effectiveness of ...
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... Researchers at King,s College London have discovered how coral ... UV rays, leading scientists to believe these compounds could ... for humans. , The team has begun to uncover ... are produced and eventually hope to recreate them synthetically ...
... From medicine and food to energy and agriculture, ... to the challenges faced by societies in the 21st ... development of gluten-free wheat, could bring hope to those ... the world population nears seven billion people, biotechnology plays ...
... and the Child & Family Research Institute have shown that ... imprint on their sons, or daughters, genes an imprint ... are expressed later in life. The study, published online ... epigenetics the expression of genes as opposed to the ...
Cached Biology News:Tropical coral could be used to create novel sunscreens for human use, say scientists 2Tropical coral could be used to create novel sunscreens for human use, say scientists 3Parents' stress leaves lasting marks on children’s genes: UBC-CFRI research 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Biology Products: